E

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021
E

Fifteen AACR21 On Demand Presentations To Watch

Noteworthy AACR21 on-demand presentations.

March 23, 2021
E

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021
E

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021
E

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021
E

Highlights of Saturday at ASH20 Part 1

Commentary on Saturday at ASH20

December 6, 2020
E

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020
E

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020
E

The Potential of CAR-NK Cells for Cancer Immunotherapy

Will CAR-NK cells follow CAR-T cell therapies and hit prime time?

May 13, 2020
E

Life, the world, and the cell therapy universe

Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?

January 30, 2020
E

JPM20 Highlights from Day 2

Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco

January 14, 2020
E

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019
E

Key highlights on lymphomas from iCML

Round-up and analysis of key lymphoma data at iCML 2019

June 20, 2019
E

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019
E

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018
E

Innate Pharma – converting science into the clinic

An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.

March 27, 2018
E

Exploring Gamida Cell with Dr Julian Adams

A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...

March 15, 2018
E

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018
E

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017
E

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017
E

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017
E

Targeting Natural Killer Cells in AML

New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.

September 27, 2016
E

Innate Pharma at an Inflexion Point. An interview with CEO Hervé Brailly

Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company

September 20, 2016
E

Why target the Innate Immune system? An interview with Eric Vivier

Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.

September 19, 2016
E

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016
E

Will anti-KIR immunotherapy make an impact in hematologic malignancies?

Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.

December 12, 2013